UniQure's Huntington's therapy fails to significantly slow disease progression, shares plunge

UniQure NASDAQ:QURE said its gene therapy for Huntington's disease fell short of statistical significance on the main goal of slowing disease progression in a four-year analysis, sending its U.S.-listed shares plummeting 55% in premarket trading on Tuesday.In the study with 12 high-dose patients, A…